Protection from La Crosse Virus Encephalitis with Recombinant Glycoproteins: Role of Neutralizing Anti-G1 Antibodies

Overview

Journal J Virol

Publisher American Society for Microbiology

Date 1995 Jun 1

PMID 7745694

Citations 21

Authors

A Pekosz

C Griot

K Stillmock

N NATHANSON

Affiliations

Soon will be listed here.

Abstract

La Crosse virus, a member of the California serogroup of bunyaviruses, is an important cause of pediatric encephalitis in the midwestern United States. Like all bunyaviruses, La Crosse virus contains two glycoproteins, G1 and G2, the larger of which, G1, is the target of neutralizing antibodies. To develop an understanding of the role of each of the glycoproteins in the generation of a protective immune response, we immunized 1-week-old mice with three different preparations: a vaccinia virus recombinant (VV.ORF) that expresses both G1 and G2, a vaccinia virus recombinant (VV.G1) that expresses G1 only, and a truncated soluble G1 (sG1) protein prepared in a baculovirus system. Whereas VV.ORF generated a protective response that was mostly directed against G1, VV.G1 was only partially effective at inducing a neutralizing response and at protecting mice from a potentially lethal challenge with La Crosse virus. Nevertheless, a single immunization with the sG1 preparation resulted in a robust immune response and protection against La Crosse virus. These results indicate that (i) the G1 protein by itself can induce an immune response sufficient for protection from a lethal challenge with La Crosse virus, (ii) a neutralizing humoral response correlates with protection, and (iii) the context in which G1 is presented affects its immunogenicity. The key step in the defense against central nervous system infection appeared to be interruption of a transient viremia that occurred just after La Crosse virus inoculation.

Citing Articles

The Adaptive Immune Response against .

Alatrash R, Herrera B Viruses. 2024; 16(3).

PMID: 38543848 PMC: 10974645. DOI: 10.3390/v16030483.

Targeted Mutations in the Fusion Peptide Region of La Crosse Virus Attenuate Neuroinvasion and Confer Protection against Encephalitis.

Hollidge B, Salzano M, Ibrahim J, Fraser J, Wagner V, Leitner N Viruses. 2022; 14(7).

PMID: 35891445 PMC: 9317099. DOI: 10.3390/v14071464.

Monoclonal antibodies to Cache Valley virus for serological diagnosis.

Skinner B, Mikula S, Davis B, Powers J, Hughes H, Calvert A PLoS Negl Trop Dis. 2022; 16(1):e0010156.

PMID: 35073325 PMC: 8812937. DOI: 10.1371/journal.pntd.0010156.

Lymphocytes have a role in protection, but not in pathogenesis, during La Crosse Virus infection in mice.

Winkler C, Myers L, Woods T, Carmody A, Taylor K, Peterson K J Neuroinflammation. 2017; 14(1):62.

PMID: 28340587 PMC: 5364665. DOI: 10.1186/s12974-017-0836-3.

Identification and Genomic Analysis of a Novel Group C Orthobunyavirus Isolated from a Mosquito Captured near Iquitos, Peru.

Treangen T, Schoeler G, Phillippy A, Bergman N, Turell M PLoS Negl Trop Dis. 2016; 10(4):e0004440.

PMID: 27074162 PMC: 4830577. DOI: 10.1371/journal.pntd.0004440.

References

Gentsch J, Bishop D . Small viral RNA segment of bunyaviruses codes for viral nucleocapsid protein. J Virol. 1978; 28(1):417-9. PMC: 354284. DOI: 10.1128/JVI.28.1.417-419.1978. View

Livdahl T, Willey M . Prospects for an invasion: competition between Aedes albopictus and native Aedes triseriatus. Science. 1991; 253(5016):189-91. DOI: 10.1126/science.1853204. View

Shope R, Rozhon E, Bishop D . Role of the middle-sized bunyavirus RNA segment in mouse virulence. Virology. 1981; 114(1):273-6. DOI: 10.1016/0042-6822(81)90276-2. View

Shope R, Calisher C, NATHANSON N . Characterization of monoclonal antibodies against the G1 and N proteins of LaCrosse and Tahyna, two California serogroup bunyaviruses. Virology. 1982; 120(1):42-53. DOI: 10.1016/0042-6822(82)90005-8. View

Shope R, Calisher C, NATHANSON N . Monoclonal antibodies against the G1 and nucleocapsid proteins of LaCrosse and Tahyna viruses. Prog Clin Biol Res. 1983; 123:145-56. View

Fuller F, BHOWN A, Bishop D . Bunyavirus nucleoprotein, N, and a non-structural protein, NSS, are coded by overlapping reading frames in the S RNA. J Gen Virol. 1983; 64 (Pt 8):1705-14. DOI: 10.1099/0022-1317-64-8-1705. View

Kingsford L, Ishizawa L, Hill D . Biological activities of monoclonal antibodies reactive with antigenic sites mapped on the G1 glycoprotein of La Crosse virus. Virology. 1983; 129(2):443-55. DOI: 10.1016/0042-6822(83)90182-4. View

Mackett M, Smith G, Moss B . General method for production and selection of infectious vaccinia virus recombinants expressing foreign genes. J Virol. 1984; 49(3):857-64. PMC: 255547. DOI: 10.1128/JVI.49.3.857-864.1984. View

Beaty B, Calisher C . Bunyaviridae--natural history. Curr Top Microbiol Immunol. 1991; 169:27-78. View

10.

Brochier B, Kieny M, Costy F, Coppens P, Bauduin B, Lecocq J . Large-scale eradication of rabies using recombinant vaccinia-rabies vaccine. Nature. 1991; 354(6354):520-2. DOI: 10.1038/354520a0. View

11.

Schmaljohn C, Hasty S, Dalrymple J . Preparation of candidate vaccinia-vectored vaccines for haemorrhagic fever with renal syndrome. Vaccine. 1992; 10(1):10-3. DOI: 10.1016/0264-410x(92)90412-d. View

12.

Xu X, Ruo S, McCormick J, Fisher-Hoch S . Immunity to Hantavirus challenge in Meriones unguiculatus induced by vaccinia-vectored viral proteins. Am J Trop Med Hyg. 1992; 47(4):397-404. DOI: 10.4269/ajtmh.1992.47.397. View

13.

Jacoby D, Cooke C, Prabakaran I, Boland J, NATHANSON N . Expression of the La Crosse M segment proteins in a recombinant vaccinia expression system mediates pH-dependent cellular fusion. Virology. 1993; 193(2):993-6. DOI: 10.1006/viro.1993.1213. View

14.

Griot C, Pekosz A, Lukac D, Scherer S, Stillmock K, Schmeidler D . Polygenic control of neuroinvasiveness in California serogroup bunyaviruses. J Virol. 1993; 67(7):3861-7. PMC: 237751. DOI: 10.1128/JVI.67.7.3861-3867.1993. View

15.

Griot C, NATHANSON N . Molecular determinants of the virulence and infectivity of California serogroup bunyaviruses. Annu Rev Microbiol. 1993; 47:117-38. DOI: 10.1146/annurev.mi.47.100193.001001. View

16.

Roberts A, Rossier C, Kolakofsky D, NATHANSON N . Completion of the La Crosse virus genome sequence and genetic comparisons of the L proteins of the Bunyaviridae. Virology. 1995; 206(1):742-5. DOI: 10.1016/s0042-6822(95)80001-8. View

17.

Janssen R, NATHANSON N . Mechanisms of bunyavirus virulence. Comparative pathogenesis of a virulent strain of La Crosse and an avirulent strain of Tahyna virus. Lab Invest. 1984; 50(4):447-55. View

18.

. La Crosse virus G1 glycoprotein undergoes a conformational change at the pH of fusion. Virology. 1985; 140(2):209-16. DOI: 10.1016/0042-6822(85)90359-9. View

19.

Najjar J, Gentsch J, NATHANSON N . Epitopes of the G1 glycoprotein of La Crosse virus form overlapping clusters within a single antigenic site. Virology. 1985; 144(2):426-32. DOI: 10.1016/0042-6822(85)90283-1. View

20.

Janssen R, NATHANSON N, Endres M . Virulence of La Crosse virus is under polygenic control. J Virol. 1986; 59(1):1-7. PMC: 253030. DOI: 10.1128/JVI.59.1.1-7.1986. View